Chinese Journal of Dermatology ›› 2022, Vol. 55 ›› Issue (3): 272-275.doi: 10.35541/cjd.20200109

• Reviews • Previous Articles     Next Articles

Superficial fungal infections in psoriasis patients treated with IL-17 related biological agents and their management

Wang Xiaowen, Li Ruoyu   

  1. Department of Dermatology and Venereology, Peking University First Hospital, Research Center for Medical Mycology, Peking University, Beijing Key Laboratory of Molecular Diagnosis of Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
  • Received:2020-02-13 Revised:2020-08-11 Online:2022-03-15 Published:2022-03-03
  • Contact: Li Ruoyu

Abstract: 【Abstract】 This review summarizes the contribution of interleukin-17 (IL-17) to the susceptibility to mucocutaneous fungal infections, and superficial fungal infections associated with IL-17-targeting biological agents, such as secukinumab, ixekizumab, brodalumab, bimekizumab and ustekinumab, in the treatment of psoriasis. The superficial fungal infections related to the treatment with IL-17 monoclonal antibody agents are usually mild or moderate, and most of them are limited, with a good response to anti-fungal therapy. In addition, this review introduces clinical evaluation, monitoring and treatment of related superficial fungal infections, and provides a basis for safe clinical use of IL-17-targeting biologics.

Key words: Psoriasis, Biological agents, Interleukin-17, Drug toxicity, Candidiasis, cutaneous